Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Igor Puzanov

1-50 of 60 results

View this query on the Wikidata Query Service
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

scientific article (publication date: April 2014)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

scientific article
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

scientific article published on March 27, 2012
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

scientific article published on 30 March 2015
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

scientific article
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

scientific article
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

scientific article published on 13 June 2016
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

scientific article
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

scientific article
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

scientific article
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

scientific article published on 08 September 2008
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

scientific article
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

scientific article published on 24 June 2016
Opportunities and obstacles to combination targeted therapy in renal cell cancer.

scientific article published on January 2007
Generation of Lytic Natural Killer 1.1+, Ly-49− Cells from Multipotential Murine Bone Marrow Progenitors in a Stroma-free Culture: Definition of Cytokine Requirements and Developmental Intermediates

scientific article published on November 3, 1997
Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems

scientific article published on 01 October 1998
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

scientific article published on 21 May 2015
A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.

scientific article published on 11 September 2014
Treatment of NRAS-mutant melanoma.

scientific article published on April 2015
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma

scientific article published on 22 June 2015
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

scientific article
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.

scientific article
IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells

scientific article published on 01 November 1996
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

scientific article
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.

scientific article published on 3 February 2015
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

scientific article
Molecular targets in melanoma from angiogenesis to apoptosis.

scientific article
γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000)

scientific article published on 18 December 2012
B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.

scientific article published on May 2010
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

scientific article
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

scientific article
Targeted Molecular Therapy in Melanoma

scientific article published on September 1, 2010
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy

scientific article published on 06 June 2012
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.

scientific article
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

scientific article
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

scientific article published on 3 June 2013
Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.

scientific article published on May 2012
Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM).

scientific article
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma.

scientific article
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

scientific article
Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy

scientific article published on 10 March 2016
Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma.

scientific article published on 4 November 2015
Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab

scientific article published on 13 May 2016
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

scientific article published on 30 November 2015
A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265).

scientific article published on 4 November 2015
Ontogeny of NK cells and the bone marrow microenvironment: Where does IL15 fit in?

scientific article published on March 1, 1997
Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study

scientific article published on 01 January 2008
Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum.

scientific article published on 18 April 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.

scientific article published on 23 February 2016
A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma

scientific article

Paulina is supported by:

About Paulina

Help